Test whether under Klb (β-klotho) genetic LOF or FGFR1-block match that abolishes FGF21-class longevity attribution, FGF21 still retains lifespan/healthspan/metabolic phenotype on the same panel

FGF21 longevity and metabolic-healthspan benefits are often read as β-klotho/FGFR1-necessary because Zhang grounds FGF21-tg lifespan and Kharitonenkov grounds metabolic regulation, while Ding and Ogawa show βKlotho is required for FGF21 growth/metabolism — necessity against residual for that class, not a residual-positive organismal longevity H2H. This discussion asks whether, once Klb LOF or FGFR1-block abolishes FGF21-class longevity attribution, FGF21 still retains lifespan/healthspan/metabolic phenotype on the same rodent panel — without inventing residual-positive outcomes or treating Zhang WT-Klb phenotype or Ding/Ogawa metabolic necessity as organismal residual H2H.

Claim

On a pre-registered rodent metabolic/healthspan panel (Zhang/Kharitonenkov-class) with FGF21 (transgenic overexpression or exogenous FGF21-class ligand) vs vehicle under Klb (β-klotho) genetic LOF or FGFR1-block match at a lock that abolishes FGF21-class longevity / metabolic-healthspan attribution vs Klb/FGFR1-intact concurrent controls, locking FGF21-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic endpoint within the refute window; full lifespan only as secondary, not gate): under that abolish lock, same-panel early healthspan/metabolic improvement (FGF21 vs vehicle under abolish) retains ≥50% of the FGF21 vs vehicle early healthspan/metabolic improvement on Klb/FGFR1-intact concurrent controls on the same panel (named comparator = FGF21 vs vehicle early healthspan/metabolic Δ on Klb/FGFR1-intact arm; units as pre-specified; α/N pre-specified) — assumption-kill / klb-insufficiency of “FGF21 longevity/metabolic-healthspan = mere β-klotho/FGFR1-necessary bridge with possible residual.” Residual-positive FGF21 lifespan or healthspan H2H under Klb LOF or FGFR1-block abolish = UNKNOWN (do not invent residual). Ding/Ogawa metabolic necessity is AGAINST residual for growth/metabolism endpoints (not organismal residual-positive longevity H2H). Prefer cell/tissue/block-QC (adipocyte glucose-uptake / MAPK QC confirming abolish) before new animal longevity; in vivo healthspan panel remains primary kill path within 6w.

Why it matters

FGF21 longevity and metabolic-healthspan benefits are often framed as β-klotho/FGFR1–necessary because Zhang grounds FGF21-tg lifespan and Kharitonenkov grounds metabolic regulation, yet a matched residual-positive FGF21 lifespan/healthspan H2H under Klb LOF or FGFR1-block abolish remains UNKNOWN (Ding shows all FGF21 growth/metabolism effects lost in Klb-/- — metabolic necessity AGAINST residual for that class, not organismal residual-positive longevity H2H; Ogawa shows BetaKlotho required for metabolic activity; Foltz adipose FGFR1 KO refractory to FGF21 metabolic benefit; Bookout CNS Klb required for metabolic/growth/circadian; Zhang is WT Klb phenotype ≠ residual). L27 asks whether, once Klb LOF or FGFR1-block abolishes FGF21-class longevity attribution, FGF21 still retains lifespan/healthspan/metabolic phenotype on the same panel — longevity/healthspan ≠ mere β-klotho/FGFR1-sole-necessity bridge with invented residual. Distinct from L15–L24 insufficiency series and especially L25 (resveratrol residual under SIRT1 LOF/EX527 — FGF21/Klb ≠ SIRT1) and L26 (melatonin residual under luzindole/Mtnr1a/b — FGF21/Klb ≠ MT/melatonin; MT ≠ Klb CRITICAL); NOT NAD-after-senolysis; NOT FOXO4×LOF; NOT MB/MAOI; NOT BPC skip-list. Soft-claims: discussion — residual-positive FGF21 under Klb/FGFR1 abolish H2H UNKNOWN; metabolic necessity ≠ organismal residual-positive; PRIOR_ART PARTIAL (phenotype + metabolic Klb/FGFR1 necessity FOUND; residual-positive longevity absent; organismal longevity necessity EMPTY; Foltz/Bookout promoted outside public prior_art); soft-complete empty ≠ novelty / ≠ failure; L1–L26 ≠ proof.

Mechanism sketch

klb-insufficiency assumption-kill: Zhang eLife grounds FGF21 transgenic overexpression lifespan extension in mice (blunts hepatic GH/IGF-1; AMPK/mTOR/NAD markers unaffected) — phenotype founding in WT Klb without Klb-LOF/FGFR1 residual arm (honesty: WT Klb ≠ residual H2H); Kharitonenkov JCI grounds FGF-21 as metabolic regulator (adipocyte glucose uptake; DIO-resistant TG; lowers glucose/TG) without Klb-abolish residual arm; Ding Cell Metab grounds whole-body βKlotho KO — all FGF21 growth/metabolism effects lost — NECESSITY AGAINST residual for metabolic/growth (≠ residual-positive; ≠ organismal longevity residual H2H); Ogawa PNAS grounds BetaKlotho required for FGF21 metabolic activity (FGFR1c/4 cofactor). Prefer cell/tissue/block-QC confirming abolish of FGF21-class control (adipocyte glucose-uptake / MAPK) before new animal longevity runs; primary kill path remains a matched rodent ± FGF21 ± Klb LOF (or FGFR1-block match) early healthspan/metabolic panel within the refute window; full lifespan only secondary; do not invent residual; do not treat Ding/Ogawa metabolic necessity as organismal residual-positive longevity; do not collapse to L26 MT (MT ≠ Klb) or L25 SIRT1. Competing caveats: abolish-fail (block not actually abolishing FGF21-class control benefit) / FGF21-alone-null on Klb/FGFR1-intact arm / underpowered strata / referee-assay mismatch vs Zhang/Kharitonenkov-class lock leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ failure; L15–L24 ≠ this; L25 ≠ this (FGF21/Klb ≠ SIRT1); L26 ≠ this (MT ≠ Klb). NOT NAD-after-senolysis (SERIES_FROZEN). Do not invent residual effect sizes.

Prior art

• PMID 23066506 / DOI 10.7554/eLife.00065 / PMC3466591 — Zhang: FGF21 transgenic overexpression markedly extends lifespan in mice (blunts hepatic GH/IGF-1; no food-intake reduction; NAD+/AMPK/mTOR markers unaffected) — founding FGF21-class longevity phenotype; WT Klb context; no Klb-LOF or FGFR1-block residual lifespan H2H; honesty: WT Klb ≠ residual H2H.
• PMID 15902306 / DOI 10.1172/JCI23606 / PMC1088017 — Kharitonenkov: FGF-21 as novel metabolic regulator (glucose uptake adipocytes; TG mice DIO-resistant; therapeutic FGF-21 lowers glucose/TG in ob/ob, db/db) — phenotype metabolic founding; no Klb-abolish residual arm.
• PMID 22958921 / DOI 10.1016/j.cmet.2012.08.002 / PMC3447537 — Ding: whole-body βKlotho KO — all FGF21 effects on growth and metabolism lost; adipose-selective Klb KO blocks acute insulin-sensitizing effects — NECESSITY AGAINST residual for metabolic/growth; ≠ residual-positive; ≠ organismal longevity residual H2H.
• PMID 17452648 / DOI 10.1073/pnas.0701600104 / PMC1855074 — Ogawa: BetaKlotho required for FGF21 metabolic activity (physical interaction FGFR1c/4; siRNA knockdown diminishes adipocyte glucose uptake; in vivo MAPK in WAT where βKlotho expressed) — NECESSITY metabolic cofactor; ≠ residual-positive longevity H2H.

Baseline claimed

Under Klb (β-klotho) genetic LOF or FGFR1-block match that abolishes FGF21-class longevity / metabolic-healthspan attribution, FGF21 still retains lifespan / healthspan / metabolic phenotype on the same panel — or Zhang 2012 FGF21-tg lifespan settles residual under Klb block / Kharitonenkov 2005 settles residual under Klb abolish / Ding 2012 or Ogawa 2007 support residual-positive under Klb LOF / Foltz 2012 FGFR1 KO settles organismal residual-positive longevity / Bookout 2013 CNS Klb settles residual lifespan / Gliniak 2025 DIO longevity proves residual under Klb LOF / L15 Oh organ-age / L16 tissue-vs-blood under D+Q / L17 intermittent-rapa FKBP / L18 17α-E2 caloric-match / L19 acarbose glycemic-match / L20 SPD/ATG bulk autophagy / L21 UA/mitophagy / L22 metformin/AMPK / L23 lithium/GSK3 / L24 canagliflozin/SGLT2 / L25 resveratrol/SIRT1 / L26 melatonin/MT / L1–L26 already settle the residual H2H.

Baseline measured

Zhang FGF21-tg lifespan LITERATURE phenotype founding prior in WT Klb without Klb-LOF/FGFR1 residual arm — WT Klb ≠ residual H2H (PMID 23066506). Kharitonenkov FGF-21 metabolic LITERATURE phenotype founding without Klb-abolish residual arm (PMID 15902306). Ding βKlotho KO LITERATURE NECESSITY AGAINST residual for metabolic/growth — all FGF21 growth/metabolism effects lost; ≠ residual-positive; ≠ organismal longevity residual H2H (PMID 22958921). Ogawa BetaKlotho LITERATURE NECESSITY metabolic cofactor ≠ residual-positive longevity (PMID 17452648). Foltz adipose FGFR1 KO refractory to FGF21 metabolic LITERATURE FGFR1 necessity — OUT of public prior_art ≤4 (PMID 23197570). Bookout CNS Klb required for FGF21 metabolic/growth/circadian LITERATURE CNS Klb necessity — OUT of public prior_art (PMID 23933984). Gliniak DIO longevity still WT Klb LITERATURE adjacent phenotype — EXCLUDED as residual anchor (PMID 40527315). Residual-positive FGF21 lifespan or healthspan H2H under Klb LOF or FGFR1-block that abolishes FGF21-class control UNKNOWN (soft-complete Q_resid/Q_resid_strict/Q_resid_life_h2h/Q_necess_life = NON-MATCH/EMPTY/OFF-PANEL; no residual-positive organismal longevity). Block-arm early healthspan/metabolic improvement retains ≥50% of Klb/FGFR1-intact FGF21 vs vehicle early healthspan/metabolic improvement PREDICTION. L15 ≠ L27; L16 ≠ L27; L17 ≠ L27; L18 ≠ L27; L19 ≠ L27; L20 ≠ L27 (FGF21/Klb ≠ bulk ATG); L21 ≠ L27 (FGF21/Klb ≠ mitophagy); L22 ≠ L27 (Klb/FGFR1 ≠ AMPK primary; FGF21 ≠ metformin; Zhang AMPK markers unaffected); L23 ≠ L27 (FGF21/Klb ≠ GSK3); L24 ≠ L27 (FGF21/Klb ≠ SGLT2); L25 ≠ L27 (FGF21/Klb ≠ SIRT1); L26 ≠ L27 (FGF21/Klb ≠ MT/melatonin; MT ≠ Klb CRITICAL); L1–L26 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT NAD-after-senolysis. Do not invent residual.

Actionable limitations

1. Do not treat L1–L26 as proving L27 — new parent area fgf21-klb-insufficiency; Zhang/Kharitonenkov/Ding/Ogawa layers are phenotype or metabolic necessity, not residual-positive H2H under Klb/FGFR1 abolish for longevity class; soft-complete empty ≠ demonstrated prediction-failure; do not invent residual; do not collapse to L26 MT (MT ≠ Klb) or L25 SIRT1.
2. 23066506 is WT Klb phenotype ≠ residual; 15902306 lacks Klb-abolish residual arm; 22958921/17452648 are NECESSITY AGAINST residual for metabolic/growth (not residual-positive); 23197570/23933984 FGFR1/CNS-Klb necessity OUT of public prior_art; matched residual-positive FGF21 lifespan/healthspan H2H UNKNOWN; organismal longevity-class necessity EMPTY — PRIOR_ART PARTIAL.
3. L15 ≠ L27; L16 ≠ L27; L17 ≠ L27; L18 ≠ L27; L19 ≠ L27; L20 ≠ L27 (FGF21/Klb ≠ bulk ATG); L21 ≠ L27 (FGF21/Klb ≠ mitophagy); L22 ≠ L27 (Klb/FGFR1 ≠ AMPK; FGF21 ≠ metformin); L23 ≠ L27 (FGF21/Klb ≠ GSK3); L24 ≠ L27 (FGF21/Klb ≠ SGLT2); L25 ≠ L27 (FGF21/Klb ≠ SIRT1); L26 ≠ L27 (MT ≠ Klb CRITICAL); NAD/CD38/senolysis soft-complete NON-MATCH — NOT SERIES_FROZEN NAD-after-senolysis; no dosing; ip_class ≠ none; orthosteric_drift=false.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion

Prediction variables

Ablate

• remove - remove: matched FGF21 ± Klb LOF (or FGFR1-block abolishing FGF21-class control) vs Klb/FGFR1-intact concurrent controls with same-panel early healthspan/metabolic residual co-readout: Without the abolish-lock × residual healthspan/metabolic H2H on the same panel, separate Zhang/Kharitonenkov phenotype LITERATURE and Ding/Ogawa metabolic-necessity LITERATURE cannot show longevity/healthspan ≠ mere β-klotho/FGFR1-sole-necessity bridge, and residual-positive FGF21 stays untested (not invented).
• remove block-arm early healthspan/metabolic improvement scored against the Klb/FGFR1-intact FGF21 vs vehicle early healthspan/metabolic improvement as named comparator under the abolished-control lock (vs phenotype-alone): Without the intact-arm FGF21 vs vehicle early healthspan/metabolic comparator under the abolish lock, the card collapses into unmatched phenotype framing and loses the klb-insufficiency assumption-kill.
• remove L15≠L27 + L16≠L27 + L17≠L27 + L18≠L27 + L19≠L27 + L20≠L27 + L21≠L27 + L22≠L27 + L23≠L27 + L24≠L27 + L25≠L27 + L26≠L27 + L1–L26≠proof + soft-complete-empty≠novelty + residual-UNKNOWN + Zhang-WT-Klb≠residual + Ding/Ogawa-necessity≠residual-positive + MT≠Klb + FGF21/Klb≠SIRT1 + NOT-NAD-after-senolysis discipline: Treating L15 Oh organ-age, L16 tissue-vs-blood, L17 intermittent-rapa FKBP, L18 caloric-match, L19 glycemic-match, L20 SPD/ATG, L21 UA/mitophagy, L22 metformin/AMPK, L23 lithium/GSK3, L24 canagliflozin/SGLT2, L25 resveratrol/SIRT1, L26 melatonin/MT (via MT≠Klb collapse), Zhang WT Klb as residual, Ding/Ogawa as residual-positive, empty PubMed, or NAD/CD38 adjacent hits as already deciding residual-positive under Klb/FGFR1 abolish — or inventing residual effect sizes — would invent a result left UNKNOWN.

Refute if

On the pre-registered rodent metabolic/healthspan panel (Zhang/Kharitonenkov-class) where Klb LOF or FGFR1-block locks FGF21-class control benefit abolished, same-panel early healthspan/metabolic improvement (FGF21 vs vehicle under abolish) is <50% of the FGF21 vs vehicle early healthspan/metabolic improvement on Klb/FGFR1-intact concurrent controls — so FGF21 longevity/metabolic-healthspan DOES reduce to mere β-klotho/FGFR1-necessary bridge under abolished FGF21-class control and the klb-insufficiency assumption-kill fails — when abolish-fail, FGF21-alone-null, underpowered-strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one rodent FGF21 (tg or exogenous) vs vehicle × Klb LOF (or FGFR1-block) regimen with abolished FGF21-class-control-benefit definition, prefer cell/tissue/block-QC before new animal longevity, primary early healthspan/metabolic referee within the refute window, optional full-lifespan co-readout, and ≥50%-of-intact-FGF21-vs-vehicle early healthspan/metabolic retention gate before claiming residual under Klb/FGFR1 abolish; do not invent residual; do not treat Zhang WT Klb phenotype or Kharitonenkov metabolic founding or Ding/Ogawa metabolic necessity or Foltz FGFR1 necessity or Bookout CNS Klb necessity or Gliniak DIO longevity (WT Klb) or L15 or L16 or L17 or L18 or L19 or L20 or L21 or L22 or L23 or L24 or L25 or L26 or L1–L26 as residual-positive organismal longevity proof; FGF21/Klb ≠ SIRT1; FGF21/Klb ≠ MT/melatonin; MT ≠ Klb; FGF21/Klb ≠ bulk ATG; FGF21/Klb ≠ mitophagy; FGF21/Klb ≠ GSK3; FGF21/Klb ≠ SGLT2; Klb/FGFR1 ≠ AMPK primary; NOT NAD-after-senolysis; no dosing.

Cheap IP

kill_cost_tier=2 · time_to_refute=6w · ip_class=klb-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Zhang 2012 FGF21-tg lifespan (WT Klb) × Kharitonenkov 2005 FGF-21 metabolic × Ding 2012 βKlotho required (NECESSITY AGAINST residual metabolic/growth) × Ogawa 2007 BetaKlotho required metabolic — Foltz 2012 adipose FGFR1 KO refractory (FGFR1 necessity; OUT of public prior_art) × Bookout 2013 CNS Klb required (OUT of public) — L15 (DunedinPACE-without-GrimAge × Oh organ-age — not FGF21 Klb-block residual; L15 ≠ L27); L16 (tissue SA-β-gal/p16 vs blood under D+Q — not klb-insufficiency residual; L16 ≠ L27); L17 (intermittent-rapa FKBP-high tissue mTORC2 — not FGF21 residual under Klb/FGFR1; L17 ≠ L27); L18 (17α-E2 × caloric-match residual — different drug/modality; L18 ≠ L27); L19 (acarbose × glycemic-match residual — different drug/modality; L19 ≠ L27); L20 (SPD residual under ATG5/7 / autophagy-insufficiency — FGF21/Klb ≠ bulk ATG; L20 ≠ L27); L21 (UA residual under PINK1/Parkin / mitophagy-insufficiency — FGF21/Klb ≠ mitophagy; L21 ≠ L27); L22 (metformin residual under AMPK LOF/Compound C / ampk-insufficiency — Klb/FGFR1 ≠ AMPK primary; FGF21 ≠ metformin; L22 ≠ L27); L23 (lithium residual under GSK3 LOF / gsk3-insufficiency — FGF21/Klb ≠ GSK3; L23 ≠ L27); L24 (canagliflozin residual under SGLT2 LOF / sglt2-insufficiency — FGF21/Klb ≠ SGLT2; L24 ≠ L27); L25 (resveratrol residual under SIRT1 LOF/EX527 / sirt1-insufficiency — FGF21/Klb ≠ SIRT1; L25 ≠ L27); L26 (melatonin residual under luzindole/Mtnr1a/b / mt-receptor-insufficiency — FGF21/Klb ≠ MT/melatonin; MT ≠ Klb CRITICAL; L26 ≠ L27); L1–L26 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/L27.card.md card_sha256: 1c3dcebc2dfdc97c8e405eeaeacdc20081bf82f2d6c8cef875ac1320bd0d18c2

Mol Labs public report: PENDING dual-publish